



















# A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors

Chester E. Chamberlain, Michael S. German, Katherine Yang, et al.

*Mol Cancer Ther* 2018;17:2702-2709. Published OnlineFirst September 25, 2018.

**Updated version** Access the most recent version of this article at:  
doi:[10.1158/1535-7163.MCT-17-1204](https://doi.org/10.1158/1535-7163.MCT-17-1204)

**Supplementary Material** Access the most recent supplemental material at:  
<http://mct.aacrjournals.org/content/suppl/2018/09/25/1535-7163.MCT-17-1204.DC1>

**Cited articles** This article cites 56 articles, 18 of which you can access for free at:  
<http://mct.aacrjournals.org/content/17/12/2702.full#ref-list-1>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://mct.aacrjournals.org/content/17/12/2702>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.